trial

Antipsychotics and Risk of Hyperglycemic Emergencies

NCTId NCT02582736
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 725,489 (actual)
Sponsored by Canadian Network for Observational Drug Effect Studies, CNODES
Primary completion 2012-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
725,489 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2012-04
Primary completion
2012-12
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
OlanzapineRisperidoneatypical antipsychotics (other)typical antipsychotics

Sponsors

Canadian Network for Observational Drug Effect Studies, CNODESLead Sponsor
Drug Safety and Effectiveness Network, CanadaCollaborator
Canadian Institutes of Health Research (CIHR)Collaborator

Investigators

1
Lorraine Lipscombe, MD, MScPrincipal Investigator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
725,489
Phase
NA
Primary Completion Date
2012-12
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Risperidone
drug
atypical antipsychotics (other)
drug
typical antipsychotics
drug
lead_sponsor
Canadian Network for Observational Drug Effect Studies, CNODES
company
collaborator
Drug Safety and Effectiveness Network, Canada
company
Canadian Institutes of Health Research (CIHR)
company
indication
Bipolar Disorder
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
investigator
Lorraine Lipscombe, MD, MSc
person